<DOC>
	<DOCNO>NCT02913196</DOCNO>
	<brief_summary>This multi-center , Phase I study apalutamide combination abiraterone acetate , docetaxel prednisone patient metastatic mastrate resistant prostate cancer ( mCRPC ) . This study design determine dose apalutamide administer safely combination abiraterone acetate , docetaxel prednisone .</brief_summary>
	<brief_title>Phase I Trial Apalutamide Plus Abiraterone Acetate , Docetaxel , Prednisone Patients With mCRPC</brief_title>
	<detailed_description>Subjects enrol three 3-6-subject cohort administer combination ( apalutamide , abiraterone acetate docetaxel plus prednisone ) accord dose-escalation schedule . The first dose docetaxel infusion begin Day 1 Cycle 1 . Daily oral apalutamide , abiraterone acetate plus twice-daily oral prednisone begin Day 1 Cycle 1 . Docetaxel 1-hour infusion administer intravenously every 3 week ( Q3W ) , precede oral dexamethasone . While subject receive chemotherapy , treatment cycle define 21 day . Dose limit toxicity ( DLT ) determination base toxicity observe within initial 2 cycle define 6 week . DLT assess start third docetaxel infusion . Once combination dose determine safe ( i.e . 2 6 subject experience DLT ) , next cohort enroll . Subjects remain allocated combination dose maximum tolerate dose ( MTD ) determine . The primary objective determine safe dose combination apalutamide plus abiraterone acetate , docetaxel , prednisone subject mCRPC .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>1 . Histologically cytologically confirm adenocarcinoma prostate 2 . Documented progressive metastatic CRPC base least one follow criterion : 1 . PSA progression accord Prostate Cancer Working Group 3 ( PCWG3 ) criteria 2 . Objective radiographic progression soft tissue , accord modify Response Evaluation Criteria In Solid Tumors ( RECIST ) bone scan 3 . ECOG performance status 02 4 . Have serum testosterone &lt; 50 ng/dL . Subjects must continue primary androgen deprivation LHRH/GnRH analogue ( agonist/antagonist ) undergone orchiectomy . 5 . Age &gt; 18 year . 6 . Patients must normal organ marrow function define : Absolute neutrophil count &gt; 1,500/cells/mm3 Hemoglobin ≥10.0 g/dL ( independent transfusion and/or growth factor within 3 month prior randomization ) Platelet count &gt; 100,000 x 109/uL ( independent transfusion and/or growth factor within 3 month prior randomization ) Serum creatinine &lt; 1.5 x upper limit normal ( ULN ) calculate creatinine clearance ≥ 60 mL/min/1.73 m2 CockcroftGault Serum albumin ≥3.5 g/dL Serum potassium ≥3.5 mmol/L 7 . Patients must able take oral medication without crush , dissolve chew tablet 8 . Ability understand willingness sign write informed consent document . 9 . Medications know low seizure threshold ( see list prohibited medication ) must discontinue substitute least 4 week prior study drug initiation . 1 . Liver Function If total bilirubin &gt; 1.5 x ULN ( NOTE : subject Gilbert 's syndrome , total bilirubin &gt; 1.5 x ULN , measure direct indirect bilirubin direct bilirubin within normal range , subject may eligible ) Alanine ( ALT ) aspartate ( AST ) aminotransferase &gt; 1.5xULN ( &gt; 5xULN subject liver metastasis ) concomitant alkaline phosphatase &gt; 2.5xULN ( &gt; 5xULN subject bone liver metastasis ) Alanine ( ALT aspartate ( AST ) aminotransferase &gt; 2.5xULN ( &gt; 5xULN subject liver metastasis 2 . Use investigational drug ( include vaccine ) implantation invasive medical device ≤4 week Cycle 1 , Day 1 current enrollment investigational drug device study 3 . Prior exposure apalutamide . Prior exposure abiraterone acetate and/or CYP17 inhibitor , enzalutamide allow ( prefer ) dose escalation period . 4 . Prior chemotherapy advance prostate cancer . Prior chemotherapy disease within 3 year . 5 . Prior systemic betaemitting boneseeking radioisotope ( i.e . strontium90 ) . 6 . Preexisting neuropathy ≥Grade 2 7 . Systemic azole treatment ( e.g . Fluconazole , itracanozole ) ≤2 week Cycle 1 Day 1 8 . Use potent inducer inhibitor CYP3A4 activity ≤2 week prior Day 1 Cycle 1 9 . History adrenal insufficiency hyperaldosteronism 10 . Active symptomatic viral hepatitis 11 . Chronic liver disease . 12 . Brain metastasis leptomeningeal disease 13 . Known allergy , hypersensitivity intolerance abiraterone acetate , apalutamide , docetaxel , dexamethasone , prednisone , excipients 14 . Use herbal , alternative food supplement ( i.e . PCSpes , Saw Palmetto , St John Wort , etc ) must discontinue treatment start . Daily Multivitamin , calcium Vitamin D allow 15 . Surgery local prostatic intervention within 30 day first dose . [ Note : Any clinically relevant sequela surgery must resolve prior Day 1 Cycle 1 ] 16 . Radiation therapy treatment prostate cancer ≤4 week Day 1 Cycle 1 17 . Current evidence following : Uncontrolled hypertension ( define blood pressure &gt; 150 mmHg systolic and/or &gt; 100 mmHg diastolic medication ) Gastrointestinal disorder affect absorption Active infection ( e.g. , human immunodeficiency virus [ HIV ] viral hepatitis ) medical condition would make prednisone/prednisolone ( corticosteroid ) use contraindicate Any chronic medical condition require high dose corticosteroid 10 mg prednisone/prednisolone daily Any condition opinion investigator , would preclude participation study . Patients baseline severe hepatic impairment ( Child Pugh Class C ) 18 . Severe unstable angina , myocardial infarction , symptomatic congestive heart failure , arterial venous thromboembolic event ( e.g. , pulmonary embolism , cerebrovascular accident include transient ischemic attack ) , clinically significant ventricular arrhythmia within 6 month prior treatment start New York Heart Association ( NYHA ) Class II IV heart disease 19 . Seizure know condition may predispose seizure ( include limit prior stroke , transient ischemic attack , loss consciousness within 1 year prior randomization , brain arteriovenous malformation ; intracranial mass schwannomas meningiomas cause edema mass effect ) . 20 . Having partner childbearing potential willing use method birth control deem acceptable principle investigator chairperson study 1 week last study drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>